Literature DB >> 21039757

More on first-in-man studies.

J M Ritter.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 21039757      PMCID： PMC2997302          DOI： 10.1111/j.1365-2125.2010.03806.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Testing new drugs in naked apes and getting the dose right in their young.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 2.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

3.  A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group.

Authors:  Michel Sibille; Alain Patat; Henri Caplain; Yves Donazzolo
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

4.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

Review 5.  Establishing risk of human experimentation with drugs: lessons from TGN1412.

Authors:  M J H Kenter; A F Cohen
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321
  5 in total
  1 in total

1.  Exploiting modern cannabinoid pharmacology for therapeutic gain?

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.